Medical Monitoring and Crisis Intervention

Cluster covering 35 related competencies for monitoring acute psychological effects, recognising and managing distress, crisis containment, emergency escalation, and rescue-medication coordination during psychedelic dosing sessions.

Stabilisation and escalation

Teaches ongoing participant contact after dosing to support stability, detect delayed adverse effects, maintain therapeutic containment, and sustain adherence to follow-up visits and outcome assessments.

Disposition and follow-up

Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.

Disposition and follow-up

Teaches how to determine when a participant is safe to leave after dosing and how to arrange appropriate supervision afterward. The competency covers psychological and physical stability, escort/support-person coordination, discharge restrictions, overnight or post-session support, and follow-up contact when needed.

Teaches continuous monitoring for distress, confusion, psychotic symptoms, suicidality, agitation, and other acute behavioral risks during and after dosing. The focus is early recognition, documentation, and escalation to clinical support when risk emerges.

Routine observation

Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.

Routine observation

Teaches monitoring and response for acute physiological risks, including vital signs, temperature, hydration, overheating, excessive fluid intake, and suspected overdose. The competency emphasizes supportive care, medical coordination, documentation, and escalation when needed.

Teaches recognition and management of expected and unexpected side effects during psychedelic or ketamine treatment. The competency emphasizes active observation, supportive response, and clinical escalation when symptoms exceed routine tolerability.

The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.

Early risk recognition

Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.

Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.

Cluster covering 2 related competencies including: Medical escalation and rescue medication use, Medical escalation and rescue medication coordination.

Stabilisation and escalation

Teaches counseling and monitoring around contraception, reproductive restrictions, pregnancy risk, and pregnancy-related discontinuation rules. Learners are trained to explain requirements clearly and respond promptly when pregnancy or reproductive-safety concerns arise.

Monitors participant physical status during study visits and identifies concerning changes requiring escalation. Vital signs and symptomatic changes are part of routine safety observation.

Teaches continuous evaluation of clinical risk and maintenance of a safe care environment throughout preparation, dosing, and follow-up. Learners monitor risk signals, apply safety procedures, and escalate care when needed.

Facilitators must be able to contain and support intense psychological distress during the session. The study notes that the experience could be emotionally difficult even when participants felt safe.

Therapists must ensure continuity of care after the acute session, including overnight observation and next-morning integration before discharge. This reflects a containment and recovery responsibility beyond the dosing period.

Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.

Cluster covering 2 related competencies including: Safety monitoring during ketamine dosing, Physiologic monitoring during ketamine administration.

The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.

Cluster covering 5 related competencies including: Cardiac safety monitoring, Ketamine infusion monitoring, Ketamine infusion administration.

Study clinicians are responsible for administering study drug, ensuring correct dose assignment, and supervising safe oral ingestion during blinded sessions. This includes verifying visit-specific randomization information and ensuring dosing is delivered under the blinded workflow.

The page points to checklists and a guide to basic medical emergencies, indicating that learners should be able to monitor safety and recognize urgent issues. The overall training context also stresses keeping both client and practitioner safe.

Reviews laboratory and ECG data for clinically relevant abnormalities and determines whether continued participation is appropriate. Escalates abnormalities requiring repeat testing or specialist input.

Respond to agitation or attempts to leave the room in a way that preserves safety for the patient and others. The therapist should use containment, redirection, and escalation protocols when needed.

Therapists must prepare the subject for residual effects after the main session and provide practical safeguards for sleep, transportation, and home support. This includes framing recurrence of symptoms in a non-alarming way.

The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.

Follows the study's operational rules for dose timing, progression, and stopping conditions. Reliable execution is necessary for both safety and interpretability of results.

Facilitators must know the risks and contraindications associated with ayahuasca use. They should identify medical and psychological factors that make participation unsafe or require extra caution.

Monitors for potential adverse effects associated with ibogaine administration and the detoxification period, even though the abstract primarily reports outcomes rather than specific events.

Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.

Ability to monitor for short-term cognitive impairment following psychedelic administration. The study included tests designed to detect decrements in attention and processing speed.

Understand that ibogaine has a significant toxicity profile, especially cardiotoxicity. Fatalities have been temporally associated with use, often in the setting of medical comorbidity, co-use, or electrolyte imbalance.

Safety monitoring in this context includes tracking not only adverse psychiatric states but also broader psychological, emotional, existential, and spiritual outcomes. Clinicians should watch for changes across multiple domains that may affect patient functioning and care needs.

Ability to observe and respond to participants during MDMA medicine sessions, including both psychological experience and physiological change. The protocol indicates an interest in psychological and physiological processes of change during treatment.

Because the protocol involved specific LSD doses, active placebo control, and session spacing, facilitators need applied skill in implementing dosing-session procedures safely and consistently. This includes maintaining therapeutic support while adhering to protocol constraints.

Learners are explicitly offered Basic Life Support training, indicating emergency readiness and medical safety preparation. The page notes DORA-required status, signaling regulatory safety relevance.

Responds to distressing anxious or psychotic reactions with verbal de-escalation and, if needed, rescue medications. Escalates intervention in a stepwise manner based on clinical response.

Track the participant’s subjective drug intensity during the active phase of the session. This includes recognizing when the participant cannot respond and how to document maximum intensity.

Therapists must remain with participants at the end of and immediately after experimental sessions until emotional stability is established. This requires real-time clinical judgment about readiness for reduced supervision.

Work within protocol-defined limits of therapist support. The trial excluded participants whose conditions could jeopardize rapport given those limits, underscoring the need for clear boundaries.

Understand that classic psychedelics can cause moderate increases in blood pressure, heart rate, temperature, and pupil size without necessarily indicating severe toxicity. Proper interpretation helps avoid overreaction while remaining vigilant.

Review laboratory and biomarker data for clinically significant abnormalities, including chemistry, hematology, coagulation, and alcohol biomarkers. This supports medical safety surveillance during follow-up.

Therapists must provide continuity, availability, and clear support structures after MDMA sessions to reduce anxiety and manage emerging difficulties. This safety net extends beyond the dosing day.

Therapists in this setting must recognize abnormal cardiovascular responses and follow protocolized responses for hypertensive crisis, angina, myocardial infarction, or stroke.

Performs targeted nasal examinations and assesses local tolerability of esketamine nasal spray. Identifies findings that could affect drug delivery, safety, or continuation.

Facilitators must protect participants and others from harm without unnecessarily restraining the participant. The guidance emphasizes containing danger rather than restraining movement.

A study physician with psychiatric and cardiovascular emergency expertise must be available during dosing. This reflects a requirement for advanced emergency readiness and clinical judgment.

Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.

Facilitators must watch for slowed breathing, sleep apnea-related hypoxia, disordered breathing, and oxygen desaturation. Oxygenation needs ongoing assessment during the acute and post-acute periods.

Carry out baseline medical safety checks prior to intervention initiation. These assessments reduce risk and support participant suitability.

Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.

Measure opioid withdrawal severity using standardized instruments and interpret symptom severity over time. Facilitators must be able to collect both objective observation and patient-reported data.

Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.

Understands and monitors concentration-related cardiac risk, especially QTc prolongation, in participants receiving noribogaine or similar agents. Uses ECG findings to support safe trial conduct and participant protection.

The study specifically reports no QT prolongation, indicating that cardiac safety was an important monitoring domain. Facilitators must be aware of relevant safety surveillance and the need to identify concerning effects.

Performs repeated blood pressure screening and interprets values against protocol thresholds before allowing dosing. This includes recognizing measurement artifact and repeating readings when needed.

Assess whether an event is related to treatment and resolve uncertainty through team discussion and regulatory escalation. The protocol uses a structured causality framework from unrelated to definitely related.

At least one therapist in the dyad must be a clinician with capability to assess and manage medical or psychiatric adverse events during the dosing session. This reflects a required competency boundary between general support and clinical responsibility.

Facilitators should know when and how to ask for help and delegate tasks. This is essential in emergencies and difficult situations.

Ability to judge clinical worsening over time and determine whether a participant can remain in the study or requires higher-level care. This is a continuing monitoring responsibility throughout the trial.

Be prepared to recognize medical deterioration and summon emergency help immediately. The manual states that providers who cannot call for emergency assistance should not provide ibogaine therapy.

Therapists/facilitators should be able to educate companions about clinical warning signs and how to contact the study team. This extends monitoring beyond the clinic and supports rapid response to deterioration.

Responds appropriately to safety threats disclosed in group therapy. Follows up on suicide, homicide, abuse, or neglect concerns and escalates when necessary.

Prevent dehydration during and after ibogaine treatment. The manual stresses that patients may not feel like drinking and that dehydration can become dangerous, especially if vomiting occurs.

Understand the unique cardiovascular hazards associated with ibogaine and the need for intensive cardiac oversight. The facilitator should know that cardiac risk is a central safety issue rather than a minor side effect.

Understands the implications of PET, MRI, blood sampling, and TMS-EEG procedures for participant comfort and safety. While not necessarily performing these procedures, the therapist/facilitator should know their risks and scheduling constraints.

Providers must be able to recognize and safely manage acute confusional states, which may look like a psychological break from reality. The emphasis is on physical safety, constant supervision, and avoiding abrupt antipsychotic intervention.

Respond promptly to complications arising during ibogaine-supported detoxification. Facilitators need a clear escalation plan for QTc prolongation and intolerable withdrawal.

Therapists/facilitators must monitor for adverse medical signs during sessions and obtain targeted testing when clinically indicated. Safety practice should balance participant comfort with symptom-triggered medical evaluation.

Monitor for cerebellar toxicity and gait disturbance because severe transient ataxia was observed in all patients in the study. The facilitator must be able to detect impaired coordination and prevent falls or injury.

Identify study-drug overdose and respond according to protocol with urgent sponsor notification and clinical monitoring. The protocol defines overdose as more than the assigned dose for that subject.

Recognizes that a study involving a psychoactive compound requires careful attention to participant safety during screening and participation. Even though the source does not detail procedures, a facilitator must anticipate risk-aware monitoring and escalation.

Confirm ongoing eligibility throughout the study and recognize conditions that require withdrawal or reassessment. Eligibility is not static and must be checked before key sessions.

Ability to support supervised at-home ketamine use when clinically appropriate. This implies monitoring and structure even outside the office setting.

Monitor body temperature during sessions and intervene if it rises beyond expected limits. The protocol specifies active cooling steps and escalation thresholds.

Monitor and address nicotine withdrawal symptoms and smoking urges across the treatment window. Facilitators help participants manage discomfort and sustain abstinence through high-risk periods.

Support patients through acute opioid withdrawal during ibogaine treatment when withdrawal symptoms are present. The source describes use of oral hydromorphone for symptom relief within the protocol.

Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.

Early risk recognition

Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

Therapists must be able to teach and coach grounding practices that help participants regulate during preparation and dosing. These methods are used before medication and during distress.

Teaches a trauma-informed stance during psychedelic work, including calm presence, non-verbal reassurance, body-aware support, somatic orientation, and containment through difficult experiences while maintaining safety and boundaries.

Facilitate trauma exposure in a structured, supportive, and protocol-consistent manner. The therapist must be able to initiate, pace, and process exposure work while maintaining adherence to PE methods.

The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.

Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.

After each MDMA session, therapists must assess whether continuing treatment is safe and clinically appropriate. The participant’s choice is respected unless safety concerns warrant exclusion.

The facilitator must ensure non-responders are transitioned safely back to clinical care. Continuity of care is explicitly required to support ongoing psychiatric treatment.

Understands the drug’s rapid absorption profile and lack of accumulation with repeated dosing. Uses this knowledge to anticipate timing of effects and safety observations.

Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.

Therapists must have a thorough understanding of MDMA’s subjective, relational, and physiological effects, including the non-linear way these may support healing. This knowledge is necessary for preparation, in-session decisions, and normalization of participant experiences.

Therapists function within a medically supervised ketamine model and must coordinate closely with clinicians responsible for dosing oversight and safety clearance. This includes understanding role boundaries and supporting monitoring workflows.

Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.

When overnight stays are required, facilitators and attendants must maintain safe observation and supportive presence without acting as outside therapists. They need to monitor comfort, safety, and emergency access overnight.

Evaluates opioid withdrawal symptoms and tracks changes over time in participants discontinuing methadone OST. Uses standardized withdrawal ratings to assess potential treatment effects and safety.

Ability to monitor for opioid use recurrence, other substance use, and ketamine misuse during the trial. The clinician must recognize relapse risk and take action when substance use worsens.

Therapists should identify or teach in-session coping tools and collaboratively plan how anxiety states will be recognized and supported.

Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.

Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.

Ensure that administration occurs within an ethically supervised research or clinical framework with informed oversight and careful risk-benefit consideration. Hallucinogenic agents require especially cautious use in vulnerable psychiatric populations.

Therapists/facilitators must fulfill professional legal duties and escalate safety or reporting concerns promptly.

Coordinate the conversion from opioid maintenance treatment to morphine-sulphate prior to ibogaine dosing, reflecting the treatment sequence described in the study. This requires careful timing and clinical oversight.

Treat consent as a continuing process rather than a one-time event. Patients must understand the treatment and retain the ability to revoke consent, with special procedures during the medication session for safety.

The therapist must recognize confusion, paranoia, referential thinking, withdrawal, or grandiosity and respond with steady trust, containment, and continued presence. Management skill is particularly important because these reactions may still be workable and may shift with proper handling.

Understand ibogaine, noribogaine, and noribogaine glucuronide disposition and how exposure relates to clinical effects. This knowledge supports safe interpretation of observed toxicity and response.

Balances potential symptom relief against known and emerging safety risks in participants with opioid dependence. Makes conservative decisions when cardiac or adverse-effect concerns outweigh anticipated benefit.

LSD-assisted psychotherapy in this study is explicitly framed as medically supervised. Therapists/facilitators need to practice within a setting capable of medical oversight and management of prolonged altered states.

Ability to correctly deliver the investigational inhaled drug using standardized vaporization procedures and participant instructions. Safe and accurate administration is central to the dosing protocol.

Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.

Evaluate whether a person is an appropriate candidate for ibogaine treatment by balancing potential benefit against medical risk. This includes identifying treatment-refractory opioid use disorder and weighing cardiotoxicity and other safety concerns against the harms of untreated substance use disorder.

Screen for cardiovascular risk before treatment because ibogaine may prolong the QT interval and has been linked to arrhythmias and deaths. Exclude or carefully manage patients with cardiac disease and other risk factors.

Exclude or defer patients whose medical risk is too high, especially those with cardiovascular disease or other major contraindications. This is central to safer administration according to the source.

Ketamine-assisted treatment in this protocol is multidisciplinary, so facilitators must work closely with study doctors and nurses. This includes coordinating preparation, understanding monitoring responsibilities, and escalating concerns appropriately.

Implement infection-prevention procedures during in-person study and dosing visits. Facilitators must screen participants, use PPE, maintain distancing when feasible, and adapt procedures based on test results or symptoms.

Knowledge of anorexia nervosa symptomatology, risk, and clinical instability relevant to screening and treatment monitoring. The study requires awareness of eating-disorder-specific risks and outcomes.

Assess for physiologic factors that may increase ibogaine-related harm, especially electrolyte abnormalities. The source identifies electrolyte screening as part of safer administration.

Knows the purpose and indications of medications maintained for side effect management or emergency use during KAP. Can explain how these medications relate to specific risks.

Understand the common and serious adverse effects, interaction risks, and monitoring needs of escitalopram. This includes cardiac, psychiatric, sexual, and withdrawal-related concerns.

Knows the use of ibogaine as a detoxification agent in medical and nonmedical settings and understands that its mechanism of action is novel and not fully established.

Facilitators need competence in working with PTSD when comorbid conditions are present. The source explicitly notes dissociation, depression, alcohol/substance use disorders, and childhood trauma.

5-MeO-DMT produces a very short but intense experience, which changes facilitation demands. Facilitators must be prepared for rapid transitions into and out of the altered state.

Because study drug delivery uses a vaporization device, staff must be able to recognize, document, and escalate device deficiencies. Device issues may have safety implications even when no patient harm occurs.

The therapist should watch for depression after the experience, particularly when insights are not translated into action. Continued support is presented as a way to reduce this risk and restore constructive orientation.

Understand the intranasal administration procedure and related local adverse effects. The facilitator must support safe delivery and monitor nasal reactions.

During onset, therapists must help the subject stay relaxed, accept changes, and avoid fixation on somatic discomfort or irrelevant ideation. Music and reassurance are highlighted as practical tools for reducing fear and helping the subject welcome altered perception.

Understands the clinical context of switching participants from methadone to morphine before study participation. Appreciates how opioid substitution transitions can affect symptom interpretation and safety monitoring.

Applies cautious patient selection when considering ibogaine for opioid detoxification, particularly for individuals with refractory opioid use disorder.

Conducts a retrospective psychiatric interview to judge minimal clinical improvement on the current antidepressant regimen. Uses multiple information sources and clinical observation to determine whether the participant meets screening requirements.

Initiates, uptitrates, and monitors quetiapine XR augmentation in the comparator arm according to age-specific schedules and tolerability. Recognizes the therapeutic minimum and discontinuation triggers.

Therapists must monitor a clinically vulnerable population experiencing recent loss and possible PGD risk. The protocol requires special attention to psychological destabilization, distress, and functional impairment.

Maintain physical, emotional, and relational safety as the primary guiding principle throughout IMAP. Therapists continuously monitor risk, reinforce boundaries, and intervene more directly when safety is compromised.

Administers repeated sublingual microdoses of 5-MeO-DMT in a controlled clinical trial setting. Must follow the assigned dose schedule and maintain blinding across active and placebo conditions.

Therapists must closely attend to the patient's speech, affect, movement, silence, and bodily signs to understand process and determine appropriate intervention. Fine-grained observation is necessary for both safety and therapeutic timing.

The facilitator must understand why bipolar II participants require enhanced monitoring and conservative dosing. The protocol is built around the risk of mood destabilization in this population.

The course explicitly includes ethical and relational considerations in crisis response. This suggests learners are trained to act with care, boundaries, and attunement when responding to acute distress.

The course is positioned as a preparedness-oriented training with self-directed preparation plus live facilitated learning. Learners are expected to internalize a framework for managing challenging or crisis moments with confidence and care.

Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.